妊娠期病毒性肝炎的治疗与预防
本文综述妊娠期病毒性肝炎的诊治与预防。不同肝炎病毒传播途径各异,需详细采集暴露史;乙肝和丙肝推荐常规产前筛查。乙肝高病毒载量(>200,000 IU/mL)孕妇孕晚期推荐替诺福韦酯预防母婴传播,新生儿出生12小时内接种免疫球蛋白和疫苗。
要点
- 乙肝和丙肝推荐常规产前筛查,其他类型多因症状或转氨酶异常被发现
- 乙肝病毒载量>200,000 IU/mL的孕妇孕晚期推荐替诺福韦酯预防垂直传播
- 乙肝暴露新生儿出生12小时内接种免疫球蛋白和单价疫苗
核心结论
- 妊娠期病毒性肝炎需根据病毒类型采取不同的筛查、预防和治疗策略。
- 乙肝高病毒载量孕妇孕晚期抗病毒预防可减少垂直传播。
- 丙肝在育龄女性中患病率上升,孕期抗病毒治疗角色受关注。
研究设计与样本
- 综述,总结妊娠期病毒性肝炎的治疗与预防证据。
主要发现
- 甲肝和戊肝经粪口传播,乙肝经垂直传播,丙肝经血传播,单纯疱疹病毒经性传播。
- 乙肝和丙肝推荐常规产前筛查,其他类型多在出现症状或常规化验转氨酶异常时发现。
- 甲肝和乙肝疫苗在妊娠期使用安全性已确立,推荐用于有感染风险的女性。
- 甲肝暴露后预防为单剂免疫球蛋白,免疫球蛋白G不可用时可用疫苗。
关键数值与推荐
- 乙肝病毒载量>200,000 IU/mL且肝炎活动的孕妇,孕晚期推荐替诺福韦酯预防垂直传播。
- 乙肝暴露新生儿出生12小时内接受免疫球蛋白G和单价出生剂量疫苗,随后完成3剂疫苗系列。
- 甲肝暴露后预防为单剂免疫球蛋白,免疫球蛋白G不可用时可用疫苗。
- 目前不推荐仅为降低垂直传播风险而对病毒性肝炎孕妇行剖宫产。
- 甲肝、乙肝和丙肝女性推荐母乳喂养。
临床怎么用
- 详细采集旅行、饮食、用药和性接触史以评估肝炎暴露风险。
- 对乙肝和丙肝行常规产前筛查,结合血清学和分子检测指导管理。
- 乙肝高病毒载量孕妇孕晚期启动替诺福韦酯预防,并确保新生儿出生12小时内免疫预防。
- 不因病毒性肝炎单独行剖宫产,甲肝、乙肝和丙肝女性鼓励母乳喂养。
局限性
- 丙肝孕期抗病毒治疗的角色尚待明确。
- 乙肝和丙肝的新预防和治疗方案仍在研究中。
- 需确保有前景的抗病毒药物和疫苗临床试验纳入妊娠和哺乳期女性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Viral hepatitis in pregnancy may be caused by many types of viruses that cause systemic infection or target hepatocytes in their pathogenesis. Because viral hepatitis during pregnancy may represent acute or chronic infection or the reactivation of a prior infection, a high clinical suspicion, medical history review, and awareness of risk factors for the acquisition of infection are important management principles. The route of infection varies widely and ranges from fecal-oral transmission for the hepatitis A and E viruses to vertical transmission for hepatitis B, blood-borne transmission for hepatitis C, and sexual transmission for the herpes simplex virus. For this reason, the exposure details about travel, food preferences, drug use, and sexual contacts are important to elicit. Although routine prenatal screening is recommended for chronic viral hepatitis caused by hepatitis B and C, most other causes of viral hepatitis in pregnancy are detected in the setting of compatible signs and symptoms (fatigue, abdominal discomfort, jaundice, scleral icterus) or incidentally noted transaminitis on routine labs. Serologic testing is helpful for diagnosis with molecular testing as indicated to guide the management of hepatitis B and C. Preventive vaccines for hepatitis A and B with established safety of use in pregnancy are recommended for women who are at risk of acquisition. Postexposure prophylaxis for hepatitis A is a single dose of immunoglobulin and vaccination can be used if immunoglobulin G is not available. Antiviral therapy with tenofovir disoproxil fumarate is recommended as prophylaxis in pregnant women with active hepatitis B and an elevated viral load (>200,000 IU/mL) during the third trimester to prevent vertical transmission. The neonate exposed to hepatitis B at birth should receive immunoglobulin G and a monovalent birth dose vaccine within 12 hours, followed by completion of the 3-dosage vaccine series. The prevalence of hepatitis C in women of reproductive age has increased in the United States, and the role of antiviral therapy during pregnancy is of great interest. Cesarean delivery is not currently recommended for the sole purpose of reducing vertical transmission risk in pregnant women with viral hepatitis. Breastfeeding is recommended in women with hepatitis A, B, and C. New and promising prevention and treatment options for hepatitis B and C are under investigation. Investigators and regulatory authorities should ensure that these clinical trials for promising antivirals and vaccines are designed to include pregnant and lactating women.
引用
- Dionne-Odom J, Cozzi GD, Franco RA, et al. Treatment and prevention of viral hepatitis in pregnancy. Am J Obstet Gynecol. 2021. PMID: 34516961. doi:10.1016/j.ajog.2021.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。